Moreover, the combination therapy downregulated the expression of matrix metalloproteinase-2 (MMP-2) and MMP-9 and inhibited the migration of GBM cells (Liu et al., 2015; Zhang et al., 2018; Ni et al., 2019). The gene discussed is MMP2; the disease is glioblastoma.